OBJECTIVE: To determine the prevalence and clinical correlates of the G84E mutation in the homeobox transcription factor, or HOXB13, gene using DNA samples from 9559 men with prostate cancer undergoing radical prostatectomy. PATIENTS AND METHODS: DNA samples from men treated with radical prostatectomy at the University of Michigan and John Hopkins University were genotyped for G84E and this was confirmed by Sanger sequencing. The frequency and distribution of this allele was determined according to specific patient characteristics (family history, age at diagnosis, pathological Gleason grade and stage). RESULTS: Of 9559 patients, 128 (1.3%) were heterozygous carriers of G84E. Patients who possessed the variant were more likely to have a family history of prostate cancer than those who did not (46.0 vs 35.4%; P = 0.006). G84E carriers were also more likely to be diagnosed at a younger age than non-carriers (55.2 years vs 58.1 years; P < 0.001). No difference in the proportion of patients diagnosed with high grade or advanced stage tumours according to carrier status was observed. CONCLUSIONS: In the present study, carriers of the rare G84E variant in HOXB13 were both younger at the time of diagnosis and more likely to have a family history of prostate cancer compared with homozygotes for the wild-type allele. No significant differences in allele frequency were detected according to selected clinical characteristics of prostate cancer. Further investigation is required to evaluate the role of HOXB13 in prostate carcinogenesis.
OBJECTIVE: To determine the prevalence and clinical correlates of the G84E mutation in the homeobox transcription factor, or HOXB13, gene using DNA samples from 9559 men with prostate cancer undergoing radical prostatectomy. PATIENTS AND METHODS: DNA samples from men treated with radical prostatectomy at the University of Michigan and John Hopkins University were genotyped for G84E and this was confirmed by Sanger sequencing. The frequency and distribution of this allele was determined according to specific patient characteristics (family history, age at diagnosis, pathological Gleason grade and stage). RESULTS: Of 9559 patients, 128 (1.3%) were heterozygous carriers of G84E. Patients who possessed the variant were more likely to have a family history of prostate cancer than those who did not (46.0 vs 35.4%; P = 0.006). G84E carriers were also more likely to be diagnosed at a younger age than non-carriers (55.2 years vs 58.1 years; P < 0.001). No difference in the proportion of patients diagnosed with high grade or advanced stage tumours according to carrier status was observed. CONCLUSIONS: In the present study, carriers of the rare G84E variant in HOXB13 were both younger at the time of diagnosis and more likely to have a family history of prostate cancer compared with homozygotes for the wild-type allele. No significant differences in allele frequency were detected according to selected clinical characteristics of prostate cancer. Further investigation is required to evaluate the role of HOXB13 in prostate carcinogenesis.
Authors: Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler Journal: N Engl J Med Date: 2012-07-19 Impact factor: 91.245
Authors: Charles M Ewing; Anna M Ray; Ethan M Lange; Kimberly A Zuhlke; Christiane M Robbins; Waibhav D Tembe; Kathleen E Wiley; Sarah D Isaacs; Dorhyun Johng; Yunfei Wang; Chris Bizon; Guifang Yan; Marta Gielzak; Alan W Partin; Vijayalakshmi Shanmugam; Tyler Izatt; Shripad Sinari; David W Craig; S Lilly Zheng; Patrick C Walsh; James E Montie; Jianfeng Xu; John D Carpten; William B Isaacs; Kathleen A Cooney Journal: N Engl J Med Date: 2012-01-12 Impact factor: 91.245
Authors: Matthew R Cooperberg; David J Pasta; Eric P Elkin; Mark S Litwin; David M Latini; Janeen Du Chane; Peter R Carroll Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Robert Karlsson; Markus Aly; Mark Clements; Lilly Zheng; Jan Adolfsson; Jianfeng Xu; Henrik Grönberg; Fredrik Wiklund Journal: Eur Urol Date: 2012-07-20 Impact factor: 20.096
Authors: John D Norris; Ching-Yi Chang; Bryan M Wittmann; Rebecca S Kunder; Huaxia Cui; Daju Fan; James D Joseph; Donald P McDonnell Journal: Mol Cell Date: 2009-11-13 Impact factor: 17.970
Authors: Jennifer L Beebe-Dimmer; Matthew Hathcock; Cecilia Yee; Linda A Okoth; Charles M Ewing; William B Isaacs; Kathleen A Cooney; Stephen N Thibodeau Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-24 Impact factor: 4.254
Authors: Kimberly A Zuhlke; Anna M Johnson; Scott A Tomlins; Nallasivam Palanisamy; John D Carpten; Ethan M Lange; William B Isaacs; Kathleen A Cooney Journal: Prostate Date: 2014-05-06 Impact factor: 4.104
Authors: Marco Randazzo; Alexander Müller; Sigrid Carlsson; Daniel Eberli; Andreas Huber; Rainer Grobholz; Lukas Manka; Ashkan Mortezavi; Tullio Sulser; Franz Recker; Maciej Kwiatkowski Journal: BJU Int Date: 2015-10-06 Impact factor: 5.588
Authors: Jennifer L Beebe-Dimmer; Ashley L Kapron; Alison M Fraser; Ken R Smith; Kathleen A Cooney Journal: J Clin Oncol Date: 2020-03-24 Impact factor: 44.544
Authors: Liesel M FitzGerald; Kelsie Raspin; James R Marthick; Matt A Field; Roslyn C Malley; Russell J Thomson; Nicholas B Blackburn; Annette Banks; Jac C Charlesworth; Shaun Donovan; Joanne L Dickinson Journal: Sci Rep Date: 2017-12-19 Impact factor: 4.379
Authors: Tamara L Lotan; Alba Torres; Miao Zhang; Jeffrey J Tosoian; Liana B Guedes; Helen Fedor; Jessica Hicks; Charles M Ewing; Sarah D Isaacs; Dorhyun Johng; Angelo M De Marzo; William B Isaacs Journal: Oncotarget Date: 2017-04-04
Authors: Martina Mijuskovic; Edward J Saunders; Daniel A Leongamornlert; Sarah Wakerell; Ian Whitmore; Tokhir Dadaev; Clara Cieza-Borrella; Koveela Govindasami; Mark N Brook; Christopher A Haiman; David V Conti; Rosalind A Eeles; Zsofia Kote-Jarai Journal: Br J Cancer Date: 2018-06-19 Impact factor: 7.640